3-nitro-benzimidic acid methyl ester | 54316-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-nitro-benzimidic acid methyl ester
• 英文别名: 3-Nitro-benzimidsaeure-methylester；3-Nitro-benziminomethylaether；methyl 3-nitrobenzimidate；methyl 3-nitrobenzenecarboximidate
• CAS: 54316-43-7
• 化学式: C₈H₈N₂O₃
• 分子量: 180.163
• InChiKey: COSSPEUPWLNZHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  78.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-nitro-benzimidic acid methyl ester 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 3-nitro-benzimidic acid methyl ester; hydrochloride
  参考文献：
  名称：

  Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists

  摘要：

  Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2,4,4-triphenylimidazoline (1), which had an IC(50) of 54 nM. Subsequent optimization led to the identification of several potent derivatives. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.101
• 作为产物：
  描述：

  间硝基苯腈 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 3-nitro-benzimidic acid methyl ester
  参考文献：
  名称：

  Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists

  摘要：

  Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2,4,4-triphenylimidazoline (1), which had an IC(50) of 54 nM. Subsequent optimization led to the identification of several potent derivatives. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.101

文献信息

• Alkali α-MnO₂/Na_xMnO₂ collaboratively catalyzed ammoxidation–Pinner tandem reaction of aldehydes
  作者：Xiuquan Jia、Jiping Ma、Min Wang、Xiaofang Li、Jin Gao、Jie Xu

  DOI：10.1039/c6cy00874g

  日期：——

  while the potassium cation promotes the formation of a redox-active α-MnO2 phase. The interface structure of α-MnO2/NaxMnO2 geometrically favors the ammoxidation–Pinner tandem reaction to synthesize imidates in a 58–96% yield from aldehydes. Thus a phase collaborative effect is observed. In the ammoxidation process, the redox cycle of MnIV/MnIII is involved and the lattice oxygen in the α-MnO2 phase acts

  串联反应是一个不断发展的领域，可以向绿色和可持续化学领域取得重要进展。在本文中，我们报道了双功能锰氧化物催化剂与接口结合的氧化还原相（α-MnO的2）和一个基本相（钠X的MnO 2）。的NaOH / Mn的摩尔比起着α-MnO的形成了极大的作用2 /钠X的MnO 2。钠阳离子为基本的Na的形成是必需的X的MnO 2，而钾阳离子促进氧化还原活性α-MnO的形成相2相。所述的接口结构的α的MnO 2 /钠X的MnO 2从几何学上讲，它有利于氨氧化-PIN串联反应以醛的形式合成酰亚胺，产率为58-96％。因此，观察到阶段协作效应。在氨氧化反应过程中，Mn的氧化还原循环IV / Mn为III是参与并在α-MnO的晶格氧2相作为活性氧种。甲醇中的OH被活化，并在Na x MnO 2的碱性位点上解离成吸附的甲氧基，从而促进Pinner合成。该方法绕过了酰亚胺合成的常规方法，该方法面临苛刻的反应条件和需要多个步骤。
• A simple and convenient one-pot method for the preparation of heteroaryl-2-imidazoles from nitriles
  作者：Matthew E. Voss、Catherine M. Beer、Scott A. Mitchell、Peter A. Blomgren、Paul E. Zhichkin

  DOI：10.1016/j.tet.2007.11.009

  日期：2008.1

  A simple, convenient and high-yielding one-pot method for the synthesis of 2-heterocycle-substituted imidazoles from the corresponding nitriles has been developed. The procedure is easily scaleable and the workup does not involve chromatography. This synthesis is also applicable to the preparation of imidazoles with electron-poor aryl substituents.

  已经开发了一种简单，方便且高产率的一锅法，用于从相应的腈中合成2-杂环取代的咪唑。该过程易于规模化，并且后处理不涉及色谱法。该合成方法也可用于制备具有贫电子芳基取代基的咪唑。
• Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
  申请人：Cell Pathways, Inc.

  公开号：US06211220B1

  公开（公告）日：2001-04-03

  A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to amino or pyridylamino cyclobutane derivatives.

  通过将受影响的细胞暴露于氨基或吡啶基氨基环丁烷衍生物，抑制肿瘤，尤其是癌症和癌前病变的方法。
• PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF
  申请人：Mi Yuan

  公开号：US20100087464A1

  公开（公告）日：2010-04-08

  The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of TrkA, TrkB, TrkC, Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKCα, Raf, ROCK-II, Rsk1, and SGK kinases, or a combination thereof.

  该发明提供了化合物及其制药组合物，作为蛋白激酶抑制剂，并提供使用这些化合物治疗、改善或预防与异常或非调节激酶活性相关的病症的方法。在某些实施例中，该发明提供使用这些化合物治疗、改善或预防涉及TrkA、TrkB、TrkC、Abl、Bcr-Abl、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKCα、Raf、ROCK-II、Rsk1和SGK激酶或其组合的疾病或疾病的方法。
• Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against <i>Chlamydia pneumoniae</i>
  作者：Leena Keurulainen、Olli Salin、Antti Siiskonen、Jan Marco Kern、Joni Alvesalo、Paula Kiuru、Matthias Maass、Jari Yli-Kauhaluoma、Pia Vuorela

  DOI：10.1021/jm1008083

  日期：2010.11.11

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.